Thus, in patients with type 2 diabetes, combination incretin therapy is poised to provide better glycemic efficacy than treatment with a GLP-1 receptor agonist alone while maintaining a good side-effect profile with respect to avoiding hypoglycemia. As Healio previously reported, top-line data from SURPASS-4, the largest and longest trial of the program to date, also demonstrated that tirzepatide significantly reduced HbA1c and body weight compared with insulin glargine (Lantus, Sanofi) for adults with type 2 diabetes at high cardiovascular risk
Animal model metabolomics studies reveal that HFD-induced NAFLD is characterized by hepatic saturated fatty acid (myristic acid, palmitic acid) and monounsaturated fatty acid (oleic acid) accumulation, accompanied by decreased gluconeogenic amino acid (glycine, alanine, aspartic acid, glutamic acid, proline) levels (95)
A patient spending $300 per month on BPC-157 for eight weeks invests roughly $600
Later studies should sample blood sugars more frequently to determine if the blood sugars and BrAC effects mirror each other